Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12277788 | 0.81 | RPS6KA3 (0.47) | MAPK14HTR1AHTR7HTR2BHTR6 | |
| SCHEMBL26452828 | 0.79 | KMT2A (0.63) | HTR1AHTR7HTR2BHTR6MAPT | |
| SCHEMBL12277760 | 0.77 | KDM4E (0.46) | MAPK14MAPK13MAPK12MAPK11THRB | |
| SCHEMBL16231397 | 0.76 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11HTR1A | |
| SCHEMBL27894706 | 0.76 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11HTR1A | |
| SCHEMBL1554445 | 0.72 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11HTR1A | |
| SCHEMBL16225617 | 0.71 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11HTR1A | |
| SCHEMBL16230706 | 0.71 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11HTR1A | |
| SCHEMBL24746876 | 0.70 | — | — | |
| SCHEMBL26452836 | 0.68 | HTR1A (0.54) | HTR1AHTR7HTR2BHTR6TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | MAPK14 2445/4885MAPK13 3078/4885MAPK12 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.